It was previously shown that AXL overexpression is associated with poor prognosis, metastasis, as well as drug resistance in various hematological and solid tumors, and that inhibition of AXL ...

Qurient Co. Ltd. (KRX: 115180) has announced the commencement of a clinical trial for adrixetinib (formerly named Q702), following the clearance of its investigational new drug (IND) application by ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...

Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not ...